Objective: Access to dialysis treatment and the types of treatments employed in Australia differs by Indigenous status. We examined whether dialysis treatment utilisation in Indigenous and non-Indigenous Australians also differs by gender.
G
ender and race interact with socioeconomic factors to influence the development of chronic kidney disease (CKD), progression to end-stage kidney disease (ESKD), access to dialysis treatment and the types of treatments prescribed. [1] [2] [3] In Australia, the age-adjusted prevalence of CKD stage 4/5 in the general, predominantly non-Indigenous, population is double in women compared with men (0.37% versus 0.19%). 4 However, the incidence of those who actually receive treatment for ESKD is nearly 40% higher for men than women (98 versus 62 per 100,000 population). 3 In regards to race, the disparity between Indigenous and non-Indigenous Australians is profound: Indigenous Australian adults have eight times the age-adjusted incidence of treated ESKD than nonIndigenous adults (79 versus 10 per 100,000). 5 Treatment rates are inextricably linked to socio-economic factors with the incidence of treated ESKD decreasing with increasing area-level socio-economic advantage in both the Indigenous 6 and non-Indigenous populations. 7, 8 The gradient in treatment rates from urban to remote regions is most pronounced within Indigenous Australian peoples with those living in remote areas having up to 30 times the national incidence of treated ESKD. 6 These different risk profiles suggest tailoring treatment approaches for specific patient groups may be beneficial, however an evidence base is required.
A broad and complex range of historical, social, cultural, geographical and economic factors, as well as the more commonly described proximal biomedical risk factors interact to influence racial differences in the incidence of ESKD, subsequent access to treatment and treatment patterns. 9 In
Australia, access to dialysis treatment and the types of treatments prescribed differ by Indigenous status. 10, 11 However, whether these racial differences in treatment patterns vary by gender is currently unknown. Acknowledging and quantifying any differences in access to and utilisation of dialysis treatment between patients on the basis of both race and gender is an important step towards optimising treatment delivery and maximising benefit for all people living with ESKD. Using a large contemporary cohort, this is the first study to examine gender differences in dialysis treatment utilisation between Indigenous and nonIndigenous Australians. 
Methods

Data source and participants
Indigenous Health Differences in dialysis treatment by gender and race
Indigenous men (406 per million population). Conversely, incidence was consistently higher in non-Indigenous men (110 per million population) compared to non-Indigenous women (52 per million population). While there was a suggestion of a downward trend in incident rates among Indigenous Australians from 2009 to 2010, this should be viewed with caution, as there may be issues with the ascertainment of an appropriate denominator in this patient cohort. There are a number of factors which contribute to incident numbers of renal replacement therapy (among both Indigenous and nonIndigenous people). It is unknown whether this stabilisation reflects the underlying rates of diabetes, rates of disease progression, referral patterns or other diseases.
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The baseline sociodemographic and clinical characteristics of each patient group are displayed in Table 1 .
Overall, a significantly higher proportion of non-Indigenous men (62%) commenced dialysis treatment during the study period (p<0.001) and initiated treatment with a higher eGFR than the other patient groups (p<0.001). The age distribution is notable for the high proportion of non-Indigenous patients aged 60 and older compared to Indigenous patients (73% versus 25%) commencing dialysis treatment. In regards to remoteness area, over 70% of nonIndigenous adults receiving treatment were residing in major cities compared to only 14% of Indigenous adults. A significantly higher proportion of Indigenous men were current or former smokers (75%) and were referred late to nephrology treatment (31%) (both p<0.001). As previously observed, diabetic nephropathy was diagnosed as the primary cause of kidney disease in 70% and comorbid diabetes mellitus observed in 82% of all Indigenous dialysis patients (both p<0.001). All comorbid conditions, except for diabetes mellitus, were diagnosed in a higher proportion of non-Indigenous men than the other patient groups (all p<0.01).
The treatment characteristics of each patient group are displayed in Supplementary  Table 1 . In summary, a higher proportion of both non-Indigenous women and men commenced treatment with peritoneal dialysis rather than hemodialysis compared to Indigenous women and men (31% versus 22%, p<0.001). Of those who received hemodialysis, a higher proportion of nonIndigenous men (42%) received prepared vascular access (AVG/AVF) rather than a catheter compared to the other patient groups (p<0.001). At final follow-up, around 30% of both non-Indigenous women and men received dialysis treatment at home compared to 21% of Indigenous men and only 13% of Indigenous women (p<0.001). Figure 2 shows the adjusted relative risks (RR) and 95% confidence intervals (CI) for dialysis treatment utilisation in each patient group. Significant interactions between gender and race were observed for all treatment characteristics; initial treatment modality (p<0.001); location of initial dialysis treatment (p<0.001); access in use at first hemodialysis (p<0.01) and location of dialysis treatment at last follow-up (p<0.05) (data not shown).
In regards to initial treatment modality, nonIndigenous women were 91% (RR=1. 
Discussion
Using a large contemporary cohort, we examined the influence of gender and race on dialysis treatment utilisation in Australia, a country with universal access to healthcare. While Indigenous status remains the key driver of differences in contemporary dialysis treatment in Australia, gender is influential. The current analysis highlights a consistently higher incidence of dialysis treatment in Indigenous women compared to Indigenous men across the study period. This pattern is different from that seen in non-Indigenous patients where incidence is consistently higher for men compared to women. The excess of ESKD in Indigenous Australians is well documented, 5, 6 with higher rates of albuminuria observed during early adulthood in both urban and remote communities. 22, 23 Microalbuminuria is a predictor of progressive kidney and cardiovascular disease in individuals with and without diabetes. Within Indigenous Australians, the higher incidence of dialysis treatment in Indigenous women is likely due to the higher rates of albuminuria observed in this group. 24 While the causal pathways are complex and multifactorial, factors that potentially contribute to the higher rates of albuminuria in Indigenous women compared to Indigenous men include increased rates of post-streptococcal glomerulonephritis during infancy and early childhood, genetic predisposition involving lower nephron numbers, and increased rates of obesity and metabolic syndrome in adolescence and adulthood leading to insulin resistance and early onset of type 2 diabetes. [24] [25] [26] These risk factors are exacerbated by inequalities in access to mainstream services including primary healthcare as well as the lower standard of health-related infrastructure in some Indigenous communities (e.g. housing, food safety, water quality, refuse and sanitation) compared to other Australians. 27 Limited access to educational and employment opportunities, increasing carer responsibilities, and exposure to violence combine to make women in some Aboriginal and Torres Strait Islander communities particularly vulnerable to disparities in access to and utilisation of health services. improved survival, health-related quality of life, and reduced healthcare costs. 28, 29 While timely patient education and support for informed decision-making has been shown to improve the uptake of home dialysis therapies 30 beliefs, attitudes and preferences towards dialysis education and decisionmaking are not well understood. Decisionmaking reflects differences in culture, medical attitudes, resource availability, health care funding, clinical appropriateness and patient preferences. 1 Patient preferences may also be influenced by life expectancy, number of hospital visits per week, ability to travel, hours per treatment, treatment time of day, subsidised transport service, and flexibility of treatment schedule. 31 The different geographical locations, whereby nearly half of the Indigenous patients live in remote or very remote areas compared to one percent of the non-Indigenous men and women also suggests itself as a cause. Preferences, especially for the Indigenous patients, are likely highly constrained by the geographic proximity to a major dialysis centre and the increased need for home resources associated with home hemodialysis (e.g. costs of home utilities and suitable water supply). The cost of hemodialysis extends beyond fiscal to the impact on patients, families, and communities of the dislocation and emotional, physical and spiritual suffering caused. 32 Indigenous patients and their healthcare providers have stressed the importance of community renal nurse support in enabling more patients to access dialysis at home. 33 Home dialysis for remote
Indigenous patients has in turn been shown to increase compliance and self-care, leading to enhanced quality of life and treatment outcomes. 34, 35 Improving the cultural competence of nonIndigenous health care providers within renal services may also improve service provision for Indigenous people with ESKD. For example, the presence of Indigenous health workers within mainstream health services is known to enhance engagement and rapport with healthcare professionals and improve treatment outcomes for Indigenous patients. 36, 37 This is the first comprehensive analysis of differences in dialysis treatment utilisation between Indigenous and non-Indigenous women and men in Australia. Strengths of the study include its large sample size, national coverage, completeness of follow-up (only 48 of 21,627 patients were lost to followup), lack of missing data and long follow-up period. However, these strengths should be balanced against several limitations. These include possible selection bias introduced through analysis of a cohort who actually commenced dialysis and potential confounding from unmeasured factors. For example, markers of socioeconomic status including data regarding household income, education and private health insurance are not collected by ANZDATA. Further, while the analysis was adjusted for number of comorbidities, severity may be a better indicator of medical suitability for different treatments. ANZDATA does not currently collect data regarding severity, however the number of comorbidities recorded in ANZDATA has been found to be a strong predictor of mortality in Indigenous and non-Indigenous dialysis patients. 40 The accuracy of Indigenous identification is also an important source of potential bias. However, a recent pilot audit found 100% agreement between the audit result and ANZDATA in regards to racial origin, providing some reassurance. 12 The extent to which selection bias may have occurred cannot be determined as it is unknown what processes occurred at the primary-care level (e.g. deciding who to refer to a nephrologist) or after referral to a nephrologist (e.g. deciding who should be offered dialysis). Importantly, likely determinants of initial treatment such as health literacy, patient motivation, medical suitability for home dialysis, distance from home to treatment centre, and attitudes to self-management are not recorded in ANZDATA.
In summary, the current analysis confirms that contemporary dialysis treatment in Australia continues to benefit the dominant nonIndigenous population over the Indigenous population, with non-Indigenous men being particularly advantaged. Ecological studies such as this are an important step in acknowledging and quantifying differences in access to and utilisation of healthcare. Results confirm the disparity in the delivery of renal care in Australia and the consequences are not just different treatment outcomes but reflect, and likely reinforce disparities in socioeconomic outcomes and life chances.
